Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

BACKGROUND: Triweekly capecitabine plus irinotecan (CAPIRI) was not a replacement for fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the treatment of metastatic colorectal cancer (mCRC) because of the potential for greater toxicity. Recently, it has reported that mCAPIRI is well tolerated and...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Clin Oncol
Autori principali: Suzuki, Nobuaki, Hazama, Shoichi, Nagasaka, Takeshi, Tanioka, Hiroaki, Iwamoto, Yasuo, Negoro, Yuji, Yamauchi, Masami, Kobayashi, Michiya, Okuda, Hiroshi, Fujishima, Noriaki, Nishimura, Taku, Yamanaka, Naoki, Toyota, Kazuhiro, Mori, Yoshiko, Nakagami, Yuki, Shimokawa, Mototsugu, Nagano, Hiroaki, Okajima, Masazumi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Singapore 2019
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6736909/
https://ncbi.nlm.nih.gov/pubmed/31144145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-019-01473-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi